ESMO25: Transforming the cancer immunotherapy field, with Po...

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.

ESMO25: On helping patients with high unmet need, with Rober...

ESMO25: The importance of personalisation, with Bayer’s Dr N...

ESMO25: On getting ahead of cancer, with J&J's Henar Hevia &...

In conversation with Johnson & Johnson experts at ESMO 2025, discussing T-cell-redirecting bispecific antibodies and the future of immunotherapy.

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.